Letter to the editor

Ve, Reuter; Ji, Epstein; Amin, MB; Fk, Mostofi

doi:10.1016/s0046-8177(99)90153-3

Cited by 32 publications

(3 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The tumour, node, and metastasis (TNM) classification from 1978 was used for histopathological classification [17]. For tumour grading, the WHO 1999 malignancy grading system was applied [18]. High-risk NMIBC was defined as all non-muscle-invasive T1 and all G3 tumours, e.g., T1G1–G3, TaG3, and primary and secondary CIS, according to EAU standards [19] and previous results from our group [5].…”

Section: Methodsmentioning

confidence: 99%

Intravesical BCG treatment causes a long-lasting reduction of recurrence and progression in patients with high-risk non-muscle-invasive bladder cancer

et al. 2018

View full text Add to dashboard Cite

show abstract

Section: Methodsmentioning

confidence: 99%

Intravesical BCG treatment causes a long-lasting reduction of recurrence and progression in patients with high-risk non-muscle-invasive bladder cancer

et al. 2018

View full text Add to dashboard Cite

show abstract

“…In brief, 1,219 patients with a new diagnosis of bladder cancer, aged 21–80 years (mean=66 years, SD=10), were recruited in 18 hospitals in Spain between 1998–2001. Sections of paraffin-embedded blocks from the initial tumor were reviewed by a panel of pathologists using the 1999 World Health Organization classification for urothelial lesions (14) with modifications as described elsewhere (15). Controls were 1,271 subjects selected from participating hospitals with diagnoses thought to be unrelated to the exposures of interest, individually matched to the cases by age at diagnosis (± 5 years), gender, ethnicity, and study area.…”

Section: Methodsmentioning

confidence: 99%

TGFB1 and TGFBR1 polymorphic variants in relationship to bladder cancer risk and prognosis

Castillejo

Rothman

Murta-Nascimento

et al. 2008

Intl Journal of Cancer

View full text Add to dashboard Cite

The transforming growth factor-beta (TGF-b) signalling pathway plays an important role in tumor development and progression. We aimed at analyzing whether 7 different common variants in genes coding for 2 key members of the TGF-b signalling pathway (TGFB1 and TGFBR1) are associated with bladder cancer risk and prognosis. A total of 1,157 cases with urothelial cell carcinoma of the bladder and 1,157 matched controls where genotyped for 3 single nucleotide polymorphisms (SNPs) in TGFB1 (rs1982073, rs1800472, rs1800471) and an additional 3 SNPs and 1 indel polymorphism in TGFBR1 (rs868, rs928180, rs334358 and rs11466445, respectively). In the case-control study, we estimated odds ratios and 95% confidence intervals for each individual genetic variant using unconditional logistic regression adjusting for age, gender, study area and smoking status. Survival analysis was performed using the Kaplan-Meier method and Cox models. The endpoints of interest were tumor relapse, progression and death from bladder cancer. All the SNPs analyzed showed a similar distribution among cases and controls. The distribution of the TGFBR1*6A allele (rs11466445) was also similar among cases and controls, indicating no association with bladder cancer risk. Similarly, none of the haplotypes was significantly associated with bladder cancer risk. Among patients with muscle-invasive tumors, we found a significant association between TGFBR1-rs868 and disease-specific mortality with an allele dosage effect (p-trend 5 0.003). In conclusion, the genetic variants analyzed were not associated with an increased risk of bladder cancer. The association of TGFBR1-rs868 with outcome should be validated in independent patient series.

show abstract

“…The new classification subcategorizes superficial bladder cancer (SBC) into papilloma, PUNLMP (papillary urothelial neoplasm of low malignant potential) and TCC LG (transitional cell carcinoma low grade) corresponding to G1 and TCC HG (transitional cell carcinoma high grade) corresponding to G2 and G3. [568] T1 tumors have also been sub-stratified in to T1a, T1b and T1c based on the relation to the muscularis mucosa. However, there appears to be a great inter-observer variation amongst pathologists.…”

Section: Methodsmentioning

confidence: 99%

Staging of transitional cell carcinoma: Has anything changed?

Kulkarni¹,

Bakshi²

2008

Indian J Urol

View full text Add to dashboard Cite

Objective:This article is a systematic review of various changes in the evolution of the contemporary clinico-pathological staging of transitional cell carcinoma (TCC).Materials and Methods:A thorough search of the literature was done by Medline and other internet references.Results:Accurate staging of TCC is necessary for designing optimal therapy in clinical practice. Further, the current emphasis on bladder conservation and improved long-term disease free survival (DFS) necessitates minimal errors in staging and it's predictability towards recurrence and progression. Traditionally, the staging of TCC revolves around clinical and pathological findings. The staging has evolved through the understanding of various clinico- pathological factors like tumor appearance, number, size, grade, depth of invasion, muscle substratification, lymphovascular invasion and has reached the standard TNM classification. Cystoscopy and transurethral resection still remain the mainstay of staging and noninvasive imaging techniques have further enhanced the accuracy.Conclusion:The TNM classification for bladder cancer is currently the gold standard for TCC.

show abstract

Letter to the editor

Cited by 32 publications

References 1 publication

Intravesical BCG treatment causes a long-lasting reduction of recurrence and progression in patients with high-risk non-muscle-invasive bladder cancer

Intravesical BCG treatment causes a long-lasting reduction of recurrence and progression in patients with high-risk non-muscle-invasive bladder cancer

TGFB1 and TGFBR1 polymorphic variants in relationship to bladder cancer risk and prognosis

Staging of transitional cell carcinoma: Has anything changed?

Contact Info

Product

Resources

About